NEW YORK (360Dx) – Chembio Diagnostics announced today a non-binding memorandum of understanding with the Massachusetts General Hospital to develop point-of-care diagnostic tests for patients with fever symptoms.

Chembio will combine its DPP technology with biomarkers developed at Mass General to develop POC tests for typhoid and febrile illness. The biomarkers were developed via high-throughput immunoproteomic technologies, Chembio said.

Financial and other terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.